A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia

Active, not recruitingOBSERVATIONAL

Enrollment

3,500

Participants

Timeline

Start Date

April 29, 2025

Primary Completion Date

November 27, 2025

Study Completion Date

November 27, 2025

Conditions

EpilepsySeizures

Interventions

DRUG

Sodium valporate

This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.

Trial Locations (1)

Sanofi-Aventis, Chilly-Mazarin